Novartis reported a narrow 1% increase in group sales to $12.4 billion in the first quarter, held back by its Sandoz generics division which encountered price competition and weak retail demand. Consumers made forward purchases of generic medicines at the start of the Covid-19 pandemic in 2020, but then demand fell off sharply in the first quarter of this year.
